Call for Abstract
Period for Abstract Submission
Thursday , November 25th, 2021 until Thursday,
January 13th, 2022 noon, JST
Abstract submission has been closed.
Abstract Submission Process
1. Presentation Style and Language
All abstracts for General Presentation must be written in English.
Lecture form | Title | Outline | Presentation Language |
---|---|---|---|
Basic Research Summit | J Wave Syndrome Summit 2022 in Japan | English |
|
Ablation Summit | Mechanism and Therapy of Ventricular Tachycardia Derived from New Mapping System | English |
|
Device Summit | 20 years from MADIT-II | English |
|
Device Summit | Remote monitoring in the future | English |
|
Device Summit | New era for cardiac pacing in heart failure | English |
|
Symposium 3 | Anti-tachycardia pacing and cardioversion: By what mechanisms do they terminate tachyarrhythmias? | English |
|
Symposium 4 | Challenges and Pitfalls of His-Purkinje Conduction System Pacing | English |
|
Symposium 9 | Risk stratifications in inherited arrhythmia syndromes: who should be treated? | English |
|
Symposium 10 | TIPS of Catheter ablation for radiation reduction | English |
|
Symposium 11 | The Role of Genetic Testing for Inherited Arrhythmia Syndromes in the Era of Next Generation Sequencer | English |
2. Body of the Abstract
There is a 250 word limit to the body of your abstract (Please do not include author name(s) and organizational affiliation(s)). It may include one diagram, which should be in GIF or JPEG format and of 300 KB or less in size. The diagram can be in either landscape or portrait orientation and will be reduced to about 75 mm x 45 mm when printed. Please note that even if you submit a color diagram, it will be printed in black and white. In case the abstract includes a diagram, the body of the abstract should be up to 150 words.
3. Registration ID and Password
Upon your abstract submission, you should “create new account” at first. With this ID and your own password you chose when you first registered as a user, you will be able to log in to your personal abstract submission page and edit or amend your abstract at any time up to the deadline of abstract submission.
※You will be responsible for safekeeping of your password and other confidential information.
4. Presentation Language for General Presentation
Please select your presentation language, among “English”, “Japanese or English” and “Japanese preferred” at the time of registration. Note that all slides and posters must be in English only.
5. Presentation Style for General Presentation
Please select your presentation style, either “oral or poster” or “poster preferred” at the time of registration.
6. Type of Presentation Language & Style
The Presentation Language and the style (oral or poster) will be determined by the congress secretariat with regard to the schedule.
7. Publication of Accepted Abstracts
Accepted abstracts, not only the body of abstract but also abstract title, author's name and organizational affiliation will be published exactly as you registered online. We recommend you to carefully read the instructions as you fill out required information.
Abstract Registration
Registration Period
To submit an abstract, please sing in form the “Abstract Submission” button at the bottom of this page and follow the instructions. The registration period starts from Thursday, November , 2021 until Thursday , January 13th, 2022 noon, JST.
Abstract Categories
The category of your abstract is required to process your application. Please choose from the following list the number that best describes the subject of your abstract.
Please make sure that No "Case reports" is accepted.
Basic /Translational Science
1 | Ion Channels and Transporters: Molecular Structure, Function, and Regulation | 6 | Computer Modeling / Simulation |
---|---|---|---|
2 | Ion Channels and Transporters: Micro Anatomy and Pathology | 7 | Intact Heart Electrophysiology (includes Pharmacology and Optical Mapping) |
3 | Genomics: Bench | 8 | Whole Animal Electrophysiology and Pharmacology (includes Neurohumoral Modulation) |
4 | Genomics: Translational | 9 | Others |
5 | Cell Physiology, Pharmacology, and Signaling |
Cardiovascular Implantable Electronic Devices
Bradycardia Devices
10 | Device Technology | 12 | Indications and Complications |
---|---|---|---|
11 | Clinical Studies | 13 | Others |
Tachycardia Devices
14 | Device Technology | 16 | Indications and Complications |
---|---|---|---|
15 | Clinical Studies | 17 | Others |
Heart Failure Management
18 | Device Technology | 20 | Indications and Complications |
---|---|---|---|
19 | Clinical Studies | 21 | Others |
Diagnostic Devices & Sensors
22 | Device Technology | 24 | Indications and Complications |
---|---|---|---|
23 | Clinical Studies | 25 | Others |
Leads & Electrodes
26 | Implantation | 29 | Clinical Studies |
---|---|---|---|
27 | Extraction / Removal | 30 | Others |
28 | Technology |
Monitoring & Outcomes
31 | Monitoring & Follow-up | 32 | Outcomes, Quality Measures & Complications |
---|
Catheter/ Surgical Ablation
SVT / AVNRT / WPW / AT
33 | Clinical Studies / Outcomes | 37 | Ablation |
---|---|---|---|
34 | Experimental Methods | 38 | Clinical Studies |
35 | Quality Measures & Complications | 39 | Drug Therapy |
36 | Mapping & Imaging | 40 | Others |
Atrial Fibrillation & Atrial Flutter
41 | Clinical Studies / Outcomes | 45 | Ablation |
---|---|---|---|
42 | Experimental Methods | 46 | Clinical Studies |
43 | Quality Measures & Complications | 47 | Others |
44 | Mapping & Imaging | 48 | Drug Therapy |
VT/VF/VPC
49 | Clinical Studies / Outcomes | 53 | Ablation |
---|---|---|---|
50 | Experimental Methods | 54 | Clinical Studies |
51 | Quality Measures & Complications | 55 | Others |
52 | Mapping & Imaging | 56 | Drug Therapy |
Clinical Electrophysiology
Sudden Cardiac Death
57 | Risk Assessment (SAECG/TWA, HRV, QT interval etc. ) | 59 | Prevention / Treatment |
---|---|---|---|
58 | Epidemiology / Physiology | 60 | Others |
Syncope & Bradycardia
61 | Mechanism / Diagnosis | 64 | Clinical Studies |
---|---|---|---|
62 | Prevention / Treatment | 65 | Others |
63 | Drug Therapy and Devices |
Pharmacology
66 | Atrial fibrillation / Atrial flutter | 69 | Heart failure |
---|---|---|---|
67 | SVT / AVNRT / WPW / AT | 70 | Others |
68 | VT / VF / VPC |
Others
71 | Others |
---|
Inherited Disorder
72 | Brugada syndrome, Early repolarization syndrome, and Idiopathic VF | 73 | LQT syndrome, ARVC, and others |
---|
Heart Failure
Cardiac Resynchronization Therapy
74 | Indications | 76 | LV Leads |
---|---|---|---|
75 | Device Technology | 77 | Others |
Non-CRT Devices for Heart Failure
78 | Autonomic Modulation | 79 | Others |
---|
Heart Failure Management
80 | Pharmacology | 82 | Monitoring |
---|---|---|---|
81 | Clinical Studies | 83 | Others |
Pediatric / Adult Congenital Heart Disease
84 | Pediatric Cardiology | 87 | Training and Education |
---|---|---|---|
85 | Adult Congenital Heart Disease | 88 | Others |
86 | Transition |
Regulatory Science
89 | Reimbursement, Regulation, and Health policy |
---|
Young Investigator Award (YIA)
Please indicate whether or not you would like your abstract to be forwarded to the YIA selection process. The final nominees will be selected based on peer-review recommendation. Those finalists will make a presentation for the final selection at the YIA session during the congress.
Eligibility for YIA
- To qualify for the YIA, candidates must be primary authors who are aged under 40 as of June 8, 2022.
- Please note that you have ever received the YIA in the past, you are not able to apply for the YIA.
- If your abstract is nominated for the YIA, you must submit a paper to the "Journal of Arrhythmia (English)".
Acceptance Results
- The final selection of submitted abstracts will be done by the congress presidents, based on the reviews of the Scientific Program Committee.
- Notification of acceptance will be sent in the middle of April to the email address that was provided during the registration process. We will also post the results on our website.
- Please note that we may not be able to fulfill all requests with regard to venue and/or program.
- If your symposium proposal is not accepted, the abstract will be forwarded for consideration as a general presentation, only in case you have chosen to.
Page to access the Abstract Registration page
Inquiries
If you have any queries about the submission process or acceptance result, please email the Congress Secretariat (E-mail: jhrs2022@ace-enterprise.net). Please make sure to indicate your registration number in your inquiry.